Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Oxford Genetics

Oxford Genetics

Oxford Genetics, also known as Oxgene, is a synthetic biology company specializing in DNA design, protein expression optimization and cell line development technologies and services.

Oxford Genetics is a leading synthetic biology company focused on developing technologies to associated with the discovery, development and production of biologics, gene therapies, cell therapies and vaccines.

License agreement

In September 2018, Oxford Genetics and ERS Genomics extended their pre-existing non-exclusive, license agreement for the use of CRISPR gene editing technology. The agreement, which previously allowed Oxford Genetics to supply CRISPR modified cell lines to the US and Europe, has been extended to include the Asia Pacific region.


In August 2018, Oxford Genetics secured a $9.6m investment. The investment comes from existing investor Mercia Technologies PLC and Invesco Perpetual. A spokesperson from Oxford Genetics made the following statement regarding the investment:

This will allow us to continue to exeed regulatory requirements and provide quality assurance for our clients. We will also add more analytical, purification and process development equipment, for instance small scale bioreactors, to enable us to fully support our clients from research up to the point of GMP bioproduction.
Series A

On March 28, 2019 Oxford Genetics completed their series A funding round with £6.5 million in funding from Canaccord Genuity Limited, Invesco Asset Management Limited, and Merica. The CEO and founder of Oxford Genetics, Ryan Cawood, made the following statement following the companies successful series A funding round:

This significant investment round will enable Oxford Genetics to further secure its market-leading position in the expanding fields of CRISPR, gene therapy and antibody engineering.


September 11, 2019
Oxford Genetics unveils OXGENE brand.
April 2019
Oxford Genetics raises a $9,080,792 venture round from Mercia Asset Management PLC.
March 28, 2019
Oxford Genetics raises a $8,000,000 series A round.
August 2017
Oxford Genetics raises a $10,477,860 venture round from Invesco Perpetual and Mercia Asset Management PLC.
June 2017
Oxford Genetics raises a $698,650 venture round from Mercia Asset Management PLC.
November 2016
Oxford Genetics raises a $2,235,680 grant from Mercia Asset Management PLC.
July 2015
Oxford Genetics raises a $698,735 venture round from Mercia Fund Management.
July 30, 2013
Oxford Genetics raises a $227,288 seed round from Mercia Fund Management.
April 28, 2011
Oxford Genetics was founded by Leonard Seymour and Ryan Cawood.

Funding Rounds


Further Resources



Golden logo
By using this site, you agree to our Terms & Conditions.